Advanced search
Publication Cover
mAbs Volume 11, 2019 - Issue 5
Submit an article Journal homepage
4,626
Views
18
CrossRef citations to date
0
Altmetric
Report

Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk

Nicoletta BiviThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-1238-3822
ORCID Icon,
Terry MooreThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
,
George RodgersThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USAORCID Iconhttp://orcid.org/0000-0001-6219-4822
ORCID Icon,
Heather DenningThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
,
Travis ShockleyThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
,
Craig A. SwearingenThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USAORCID Iconhttp://orcid.org/0000-0003-3724-4650
ORCID Icon,
Valentina GelfanovaThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USAORCID Iconhttp://orcid.org/0000-0002-9052-1621
ORCID Icon,
Boris CalderonThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USAORCID Iconhttp://orcid.org/0000-0003-1575-0739
ORCID Icon,
Daniel A. PetersonThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USAORCID Iconhttp://orcid.org/0000-0001-9649-3580
ORCID Icon,
Michael E. HodsdonThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
,
Robert W. SiegelThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USAORCID Iconhttp://orcid.org/0000-0002-0833-5580
ORCID Icon,
Richard E. HiggsThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
&
Robert J. KonradThe Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
 show all
Pages 861-869 | Received 23 Jan 2019, Accepted 19 Apr 2019, Published online: 17 May 2019

References

  • Xue L, Fiscella M, Rajadhyaksha M, Goyal J, Holland C, Gorovits B, Morimoto A. Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of pharmaceutical scientists. Aaps J. 2013;15:852–55. doi:10.1208/s12248-013-9492-4.
  • Gorovits B, Clements-Egan A, Birchler M, Liang M, Myler H, Peng K, Purushothama S, Rajadhyaksha M, Salazar-Fontana L, Sung C, et al. Pre-existing antibody: biotherapeutic modality-based review. Aaps J. 2016;18:311–20. doi:10.1208/s12248-016-9878-1.
  • van Schie KA, Wolbink GJ, Rispens T. Cross-reactive and pre-existing antibodies to therapeutic antibodies–effects on treatment and immunogenicity. MAbs. 2015;7:662–71. doi:10.1080/19420862.2015.1048411.
  • Kim HS, Kim I, Zheng L, Vernes JM, Meng YG, Spiess C. Evading pre-existing anti-hinge antibody binding by hinge engineering. MAbs. 2016;8:1536–47. doi:10.1080/19420862.2016.1196521.
  • Xue L, Rup B. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. Aaps J. 2013;15:893–96. doi:10.1208/s12248-013-9497-z.
  • Kumar SC, DelCarpini JA, Qu Q, Kane M, Gorovits B. Mitigation of pre-existing antibodies to a biotherapeutic in non-clinical species when establishing anti-drug antibody assay cutpoint. Aaps J. 2017;19:313–19. doi:10.1208/s12248-016-0011-2.
  • Schneider AK, Vainshtein I, Roskos LK, Chavez C, Sun B, Liang M. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox. J Immunol Methods. 2016;435:68–76. doi:10.1016/j.jim.2016.05.007.
  • Chen YQ, Pottanat TG, Carter QL, Troutt JS, Konrad RJ, Sloan JH. Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodies. J Immunol Methods. 2016;431:45–51. doi:10.1016/j.jim.2016.02.008.
  • Gorovits B, Wakshull E, Pillutla R, Xu Y, Manning MS, Goyal J. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J Immunol Methods. 2014;408:1–12. doi:10.1016/j.jim.2014.05.010.
  • Kaplon H, Reichert JM. Antibodies to watch in 2019. mAbs. 2019;11(2):219–38. doi:10.1080/19420862.2018.1556465.
  • Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol 2009;30:43–51. doi:10.1016/j.it.2008.10.002.
  • Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol. 1995;32:1271–81. doi:10.1016/0161-5890(95)00085-2.
  • Nasu H, Chia DS, Knutson DW, Barnett EV. Naturally occurring human antibodies to the F(ab‘)2 portion of IgG. Clin Exp Immunol. 1980;42:378–86.
  • Ruf P, Kluge M, Jager M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol. 2010;69:617–25. doi:10.1111/j.1365-2125.2010.03635.x.
  • Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Kasai R, Yoneyama K, Yoshida H, Nogami K. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1:1891–99. doi:10.1182/bloodadvances.2017006684.
  • Deora A, Hegde S, Lee J, Choi CH, Chang Q, Lee C, Eaton L, Tang H, Wang D, Lee D, et al. Transmembrane TNF-dependent uptake of anti-TNF antibodies. MAbs. 2017;9:680–95. doi:10.1080/19420862.2017.1304869.
  • Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, Serone AP, Wilson R, Chen Y, Forrest RM, et al. Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol. 2013;33:1192–203. doi:10.1007/s10875-013-9915-0.
  • Higgs RE, Knierman MD, Gelfanova V, Butler JP, Hale JE. Comprehensive label-free method for the relative quantification of proteins from biological samples. J Proteome Res. 2005;4:1442–50. doi:10.1021/pr050109b.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.